Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

ClinicalTrials.gov ID: NCT01938430

Public ClinicalTrials.gov record NCT01938430. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant

Study identification

NCT ID: NCT01938430
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Gilead Sciences; Industry
Enrollment: 339 participants

Conditions and interventions

Conditions

Chronic HCV Infection

Interventions

LDV/SOF Drug
RBV Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2013
Primary completion: Dec 31, 2014
Completion: Feb 28, 2015
Last update posted: Nov 15, 2018

2013 – 2015

United States locations

U.S. sites: 30
U.S. states: 22
U.S. cities: 28

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	85054	—
Not listed	San Diego	California	92103	—
Not listed	San Francisco	California	94143	—
Not listed	Aurora	Colorado	80045	—
Not listed	Washington D.C.	District of Columbia	20007	—
Not listed	Jacksonville	Florida	32224	—
Not listed	Miami	Florida	33136	—
Not listed	Chicago	Illinois	60611	—
Not listed	Indianapolis	Indiana	46202	—
Not listed	Kansas City	Kansas	66160	—
Not listed	Lutherville	Maryland	21093	—
Not listed	Boston	Massachusetts	02215	—
Not listed	Ann Arbor	Michigan	48109	—
Not listed	Detroit	Michigan	48202	—
Not listed	Minneapolis	Minnesota	55455	—
Not listed	Rochester	Minnesota	55905	—
Not listed	St Louis	Missouri	63110	—
Not listed	New York	New York	10016	—
Not listed	New York	New York	10032	—
Not listed	Chapel Hill	North Carolina	27599	—
Not listed	Durham	North Carolina	27710	—
Not listed	Cleveland	Ohio	44195	—
Not listed	Portland	Oregon	97239	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Pittsburgh	Pennsylvania	15213	—
Not listed	Dallas	Texas	75246	—
Not listed	Murray	Utah	84107	—
Not listed	Richmond	Virginia	23219	—
Not listed	Seattle	Washington	98101	—
Not listed	Seattle	Washington	98104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01938430, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 15, 2018 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01938430 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →